Lord, Abbett & Co
MYGN icon

Lord, Abbett & Co’s Myriad Genetics MYGN Stock Holding History

Lord, Abbett & Co’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-678,443
Closed -$26.4M – 1011
2014
Q2 		$26.4M Buy
+678,443
New +$25.2M 0.06% 451
2013
Q4 		– Sell
-1,113,819
Closed -$26.2M – 1073
2013
Q3 		$26.2M Buy
+1,113,819
New +$31.6M 0.06% 448

Other funds holding MYGN

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Lord, Abbett & Co's MYGN Position: Q3 2014 in Review

Lord, Abbett & Co sold out of Myriad Genetics (MYGN) in Q3 2014, closing a stake of 678,443 shares — an estimated $26.4M sold.

Lord, Abbett & Co first reported a position in MYGN in Q3 2013 and held it in 2 quarters. The position peaked at $26.4M in Q2 2014. 275 funds tracked by Wall St. Rank hold MYGN as of Q3 2014.

  • Lord, Abbett & Co reported no remaining Myriad Genetics position as of Q3 2014 after selling out during the quarter.
  • Lord, Abbett & Co sold 678,443 Myriad Genetics shares in Q3 2014, an estimated $26.4M.
  • Lord, Abbett & Co first reported a position in Myriad Genetics in Q3 2013 and held it in 2 quarters.
  • Lord, Abbett & Co's Myriad Genetics position peaked at $26.4M in Q2 2014.
  • 275 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2014.

Based on Lord, Abbett & Co's 13F filing for Q3 2014, filed 14 Nov 2014.